Combination therapy in the management of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a progressive disease without a cure, which can lead to right heart failure and death. Over the past decades, several therapeutic advances have been developed for the management of PAH. Although these agents have demonstrated clinical safety and efficacy, some patients may require additional drug therapy due to a lack of response or disease progression.

[1]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[2]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[3]  M. Gulati,et al.  Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. , 2005, The American journal of cardiology.

[4]  T. Welte,et al.  Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.

[5]  G. Sybrecht,et al.  Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[6]  M. Hoeper,et al.  Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.

[7]  C. Vizza,et al.  Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study , 2009, Journal of clinical pharmacology.

[8]  R. Nagai,et al.  Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. , 2011, International heart journal.

[9]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[10]  T. Ohe,et al.  Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[11]  A. Zaiman,et al.  Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension , 2007, European Respiratory Journal.

[12]  S. Ogawa,et al.  Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[13]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[14]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[15]  R. Benza,et al.  Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. , 2008, Chest.

[16]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[17]  W. Seeger,et al.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[18]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[19]  H. Ghofrani,et al.  Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[20]  P. Escribano,et al.  Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[22]  S. Hammerschmidt,et al.  Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. , 2005, Chest.

[23]  T. Welte,et al.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[24]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[25]  M. Hoeper,et al.  Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[26]  B. Brundage,et al.  Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.